不同剂量利伐沙班应用于急性肺栓塞患者的近期疗效及安全性  

Short Term Efficacy and Safety of Rivaroxaban with Different Doses in Patients with Acute Pulmonary Embolism

作　　者：王鑫 林静[1] 龚洪申[1] WANG Xin;LIN Jing;GONG Hongshen(Zhengzhou Third People's Hospital,Zhengzhou Henan 450000,China)

机构地区：[1]郑州市第三人民医院,河南郑州450000

出　　处：《药品评价》2024年第11期1344-1347,共4页Drug Evaluation

摘　　要：目的 讨论不同剂量利伐沙班治疗急性肺栓塞患者的临床效果和安全性。方法 在2022年1月至2023年12月期间郑州市第三人民医院收治的急性肺栓塞患者中选择80例,通过随机分组法进行分组,对照组与观察组均为40例。两组均接受利伐沙班治疗,对照组前3周剂量为15 mg,每天2次,3周后剂量为20 mg,每天1次;观察组前3周剂量为10 mg,每天2次,3周后剂量为15 mg,每天1次;两组均连续用药3个月。对比两组临床效果。结果 两组治疗1个月和治疗3个月总有效率均相近(P>0.05);治疗前、后两组D-二聚体、肌钙蛋白T、B型尿钠肽前体、血氧分压及肺动脉压均差异无统计学意义(P>0.05)。观察组住院时间比对照组短(P<0.05),观察组门诊费用及住院费用均比对照组低(P<0.05),观察组出血风险发生率明显比对照组低(P<0.05)。结论 急性肺栓塞患者应用不同剂量利伐沙班治疗均可改善患者病情,但低剂量利伐沙班治疗可降低患者出血风险,缩短患者恢复时间,减轻患者经济压力。Objective To discuss the clinical efficacy and safety of different doses of rivaroxaban in the treatment of patients with acute pulmonary embolism.Methods From January 2022 to December 2023,80 patients with acute pulmonary embolism treated in Zhengzhou Third People's Hospital were selected,patients were randomly divided into groups.Both groups received rivaroxaban,the dose of the control group was 15 mg in the first 3 weeks,twice a day,after 3 weeks,the dose was 20 mg,once a day;the dose of the observation group was 10 mg in the first three weeks,twice a day,after 3 weeks,the dose was 15 mg,once a day.Both groups were treated continuously for 3 months.The clinical effects were compared.Results The total effective rates of the two groups after 1 month and 3 months of treatment were similar(P>0.05);there was no statistically significant difference in D-dimer,troponin T,B-type natriuretic peptide precursor,partial pressure of blood oxygen and pulmonary artery pressure between the two groups before and after treatment(P>0.05).The hospitalization time of the observation group was shorter than that of the control group(P<0.05),the outpatient and inpatient expenses of the observation group were lower than those of the control group(P<0.05);the incidence of bleeding risk in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Different doses of rivaroxaban can improve the condition of patients with acute pulmonary embolism.However,low-dose rivaroxaban treatment can reduce the risk of bleeding,shorten the recovery time of patients and reduce their economic pressure.

关 键 词：利伐沙班 急性肺栓塞 呼吸系统疾病 用药剂量 肺动脉压 安全性 

分 类 号：R47[医药卫生—护理学]